Otello Stampacchia
QuietNamed in filings at Omega FundsOn the current fund
- Board seats filed
- 7
Named in filings at Omega FundsOn the current fund
all filings on record
last 24 months
from a verified or cited source
| Third Arc Bio | Biotech & pharma | July 2024 | Vida Ventures |
| Ikena Oncology | Biotech & pharma | August 2023 | Atlas Venture |
| Scorpion Therapeutics | Biotech & pharma | November 2020 | Abingworth Bioventures, Atlas Venture, Vida Ventures |
| Amunix Pharmaceuticals | Biotech & pharma | February 2020 | Frazier Life Sciences |
| ESSA Pharma | Biotech & pharma | August 2019 | None on file |
| Morphic Holding | Biotech & pharma | September 2018 | Atlas Venture |
| Trevi Therapeutics | Biotech & pharma | July 2017 | NEA |
The company and date are what the SEC filing shows, not a statement of investment thesis. A partner can sit on a board for reasons that say nothing about what their firm funds today. The category is not a filing value: it is Lev’s own classification of each company, shown only when we found a specific, checkable source for it; otherwise it reads “Not yet classified.” “Also on the board from” names another tracked firm with a partner on the same board, both with a clean identity match. It is not a claim either firm led or co-led the round, and “None on file” means no other tracked firm’s partner shares this specific board seat, not that no one else invested. Sorted newest first by default; click a column to change it. Something wrong? Tell us.
Categories of companies where filings name Otello Stampacchia on the board, based on 7 filed seats with a verified or cited source.